Tag: Myelodysplastic syndrome
Zydus Lifesciences launches Revlimid generic – Lenalidomide Capsules in US
Indian pharma company Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited has launched Lenalidomide Capsules, a generic of Revlimid, in the US market. The ... Read More
Medac resubmits treosulfan NDA to FDA, says Medexus Pharmaceuticals
Medexus Pharmaceuticals said that its strategic partner medac has resubmitted the new drug application (NDA) for treosulfan with the US Food and Drug Administration (FDA). ... Read More
Sun Pharma to settle patent litigation with Celgene for generic Revlimid
Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene, a fully-owned subsidiary of Bristol Myers Squibb, ... Read More
Natco Pharma gets FDA approval for Lenalidomide Capsules
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, ... Read More
Antengene gets NMPA nod for eltanexor phase 1/2 clinical trial in myelodysplastic syndrome
Antengene has been given approval from China’s National Medical Products Administration (NMPA) for a phase 1/2 clinical trial of ATG-016 (eltanexor) in myelodysplastic syndrome (MDS). ... Read More
Curis doses first patient in CA-4948 phase 1 clinical trial in AML and MDS
CA-4948 phase 1 clinical trial : US biotech company Curis said that it has dosed the first patient with CA-4948 in a phase 1 clinical ... Read More
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the ... Read More
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More
BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome
BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program of its small molecule BTX-A51 in patients ... Read More
Armas launches Azacitidine injection for myelodysplastic syndrome in US
Armas Pharmaceuticals has launched its first injectable to the US market in the form of Azacitidine for Injection 100 MG, a Vidaza generic, used for ... Read More